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This joint themed issue of the British Journal of Pharmacology and the British Journal of 
Clinical Pharmacology stems from a joint British Pharmacological Society - Italian Society of 
Pharmacology symposium held at the 37th National Congress of the Italian Society of 
Pharmacology in Naples (Italy) from 27 to 30 October 2015. 
 
LINKED ARTICLES 
This article is part of a themed section on Targeting inflammation to reduce cardiovascular 
disease risk 
 
Abbreviations 
apoE-/-, apolipoprotein-E deficient mice; AT, adipose tissue; ATL, aspirin-triggered lipoxin 
A4; CANTOS, Canakinumab Anti-inflammatory Thrombosis Outcomes Study; COX, 
cyclooxygenase; CVD, cardiovascular diseases; DPP4, dipeptidyl peptidase 4; H2S, hydrogen 
sulphide; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; mPGES-1, microsomal prostaglandin E synthase-1; NO, nitric oxide; NK, natural 
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killer; PAR2, proteinase-activated receptor 2, PG, prostaglandin; PVAT, perivascular adipose 
tissue; tNSAIDs, traditional nonsteroidal anti-inflammatory drugs; Tsk mice, tight-skin mice. 
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Cardiovascular diseases (CVD) are the major cause of morbidity and mortality in Western 
society and are expected to be the main cause of death globally in the near future (WHO, 
2011). Basic research data strongly support a pivotal role played by inflammatory and 
immune mechanisms in CVD and studies in animal models have shown that specific 
immune-inflammatory pathways could be targeted for therapeutic utility. However, the 
translation of this knowledge to humans is still in the early stages (Welsh et al., 2017). 
New and selective immune therapies are already in use for the treatment of autoimmune 
diseases and large clinical trials have just been published or are currently evaluating the effect 
of several of these treatments on atherosclerosis and related pathologies. The outcome of 
these studies is likely to lead to new approaches in the management of vascular inflammation. 
This joint British Journal of Pharmacology and British Journal of Clinical Pharmacology 
themed issue assembles scientists that study cardiovascular inflammation over a broad range 
of topics. The aim is to provide an up-to-date overview of the current understanding of 
inflammatory and immune mechanisms in CVD, to summarise the current clinical picture 
regarding the use of anti-inflammatory drugs in cardiovascular medicine and to discuss future 
directions towards more specific immune therapies. 
The themed issue is introduced by Paul Welsh et al. (Welsh et al., 2017). The authors provide 
an overview of the key therapeutic targets in the treatment of vascular inflammation, placing 
basic research in a wider clinical perspective. Following the publication of the review article, 
data from the Phase III Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
(CANTOS: https://clinicaltrials. gov/ct2/show/NCT01327846) have been published, showing 
that canakinumab - a monoclonal antibody against IL-1β - in combination with standard 
therapy reduces recurrent cardiovascular events in people with a prior myocardial infarction 
and high levels of circulating C-reactive protein (Ridker et al., 2017). This is the first 
demonstration in a large, randomized, double blind, placebo-controlled Phase III study that 
using anti-cytokine-based therapies may be a viable approach for secondary prevention of 
atherosclerosis-related CVD. This is particularly relevant given that the use of traditional 
nonsteroidal anti-inflammatory drugs (tNSAIDs) and coxibs alike is limited by 
cardiovascular toxicity as comprehensively discussed by Carlo Patrono (Patrono, 2016). He 
provides an overview of the cardiovascular effects of cyclooxygenase (COX)-2 inhibitors, 
with a focus on the mechanisms contributing to the clinical readouts of COX-2 inhibition. 
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Several other key immune-mediated mechanisms in CVD could represent future options for 
therapeutic targeting and are discussed in detail in the current issue. T cell-mediated immune 
responses play a key role in ischaemic heart disease and in acute viral myocarditis 
(Stephenson et al., 2016). The authors propose that the development of novel specific 
diagnostic biomarkers could help to identify at an early stage patients who may benefit from 
immunomodulatory therapies. Andy Sage and Ziad Mallat (Sage and Mallat, 2017) discuss 
therapeutic strategies to target adaptive immunity to reduce atherosclerosis progression, such 
as regulatory T cell enhancing therapies, B cell depletion and vaccine-based approaches. 
Their work is complemented by the review from Amanda Foks and Johan Kuiper, where the 
authors discuss the therapeutic potential to control atherosclerosis through targeting a large 
variety of costimulatory and inhibitory immune checkpoint proteins (Foks and Kuiper, 2017). 
In addition, the role of cytotoxic lymphocytes such as natural killer cells, CD8+ T cells, 
natural killer (NK) T cells, γδ-T cells and human CD4+CD28- T cells in the development of 
atherosclerosis and unstable atheromas is reviewed (Kyaw et al., 2017). 
Inflammation and hypercholesterolemia are linked in a cycle where an excess of cholesterol 
accumulating in the vessel wall layers induces immune-inflammatory response(s), which in 
turn increase cholesterol deposition and accelerate pathology formation and development. 
Catapano et al. provide an overview of the crosstalk between inflammation and lipid 
metabolism, suggesting that the clinical impact of lipid-lowering drugs on inflammation is 
proportional to the reduction of low-density lipoprotein cholesterol (LDL-C) levels (Catapano 
et al., 2017). Concurrently, Iqbal et al. discuss the negative impact of systemic and vascular 
inflammation on the healthy metabolism and function of high-density lipoprotein cholesterol 
(HDL-C) (Iqbal et al., 2017). 
The contribution of perivascular adipose tissue (PVAT) to vascular inflammation has gained 
significant attention recently. Adipocytes, immune cells and fibroblasts within adipose tissue 
secrete a broad range of adipokines exerting endocrine or paracrine effects on the 
cardiovascular system. Among them, the role of adiponectin in cardiovascular pathogenesis, 
its capacity to regulate the crosstalk between adipose tissue and the cardiovascular system 
and its role as a biomarker in CVD are comprehensively discussed (Woodward et al., 2016). 
In the final review article, Cirino et al. discuss the role of gasotransmitters in vascular 
physiology and pathology (Cirino et al., 2017). The authors summarize what is currently 
known on the interconnection between nitric oxide (NO) and hydrogen sulfide (H2S), 
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pointing out that addressing the molecular mechanisms underlying the interaction of these 
two gas mediators may lead to the development of new therapeutic approaches. 
The themed issue ends with five original research contributions. The work by Roviezzo et al. 
analyses the effect of proteinase-activated receptor 2 (PAR2) on aortic contraction in fibrotic 
tight-skin (Tsk) mice (Roviezzo et al., 2017). Petri et al. investigated the effect of aspirin-
triggered lipoxin A4 (ATL) and its receptor Fpr2 on atherosclerosis development and 
progression, showing anti-atherogenic effects of ATL in apolipoprotein-E (apoE)-/- mice 
(Petri et al., 2017). The selective Mas receptor agonist AVE0991 was shown to exert anti-
atherosclerotic effects by affecting monocyte/macrophage recruitment to the perivascular 
space in experimental atherosclerosis (Skiba et al., 2016). Esposito et al. demonstrated that 
the dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin preserved diastolic function in a rat 
model of heart failure with preserved ejection (Esposito et al., 2016). Finally, the effect of 
inhibitors of COX-2 and microsomal prostaglandin E synthase-1 (mPGES-1) enzyme, which 
catalyses the formation of PGE2 from COX-derived PGH2, was compared in vitro on human 
vascular tone (Ozen et al., 2017). 
In summary, this joint themed issue of British Journal of Pharmacology and British Journal 
of Clinical Pharmacology will provide readers with a review of the key inflammatory and 
immune mechanisms in cardiovascular pathologies, the role of lipid and gas mediators in 
cardiovascular inflammation and the use of conventional anti-inflammatory drugs in 
cardiovascular medicine. In addition, the interplay between vascular inflammation and lipid 
metabolism, together with recent clinical trials targeting immune pathways for CVD 
prevention are comprehensively discussed. Great advances have been made in our 
understanding of immune mechanisms underlying CVD. Translation of these findings in 
clinical practice has only just begun; however, promising recent results may pave the way for 
the design of novel tissue- and or disease-specific immunomodulatory approaches to tackle 
the challenge posed by CVD on public health. 
 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
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